MannKind (MNKD) Competitors $5.57 +0.15 (+2.77%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.51 -0.06 (-1.08%) As of 09/12/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNKD vs. RGEN, ALKS, LGND, FOLD, BCRX, CLDX, INVA, NVAX, DVAX, and OPKShould you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Repligen (RGEN), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Innoviva (INVA), Novavax (NVAX), Dynavax Technologies (DVAX), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry. MannKind vs. Its Competitors Repligen Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Innoviva Novavax Dynavax Technologies OPKO Health MannKind (NASDAQ:MNKD) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations. Does the media refer more to MNKD or RGEN? In the previous week, Repligen had 6 more articles in the media than MannKind. MarketBeat recorded 17 mentions for Repligen and 11 mentions for MannKind. MannKind's average media sentiment score of 1.30 beat Repligen's score of 1.01 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, MNKD or RGEN? MannKind has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Do analysts recommend MNKD or RGEN? MannKind presently has a consensus price target of $11.17, indicating a potential upside of 100.48%. Repligen has a consensus price target of $166.67, indicating a potential upside of 46.79%. Given MannKind's stronger consensus rating and higher possible upside, equities research analysts plainly believe MannKind is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MannKind 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Repligen 0 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is MNKD or RGEN more profitable? MannKind has a net margin of 10.87% compared to Repligen's net margin of -2.05%. Repligen's return on equity of 4.61% beat MannKind's return on equity.Company Net Margins Return on Equity Return on Assets MannKind10.87% -32.60% 7.81% Repligen -2.05%4.61%3.24% Which has stronger valuation & earnings, MNKD or RGEN? MannKind has higher earnings, but lower revenue than Repligen. Repligen is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannKind$285.50M5.99$27.59M$0.1150.64Repligen$634.44M10.07-$25.51M-$0.25-454.16 Do insiders and institutionals have more ownership in MNKD or RGEN? 49.6% of MannKind shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 2.7% of MannKind shares are owned by company insiders. Comparatively, 1.2% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryMannKind beats Repligen on 10 of the 17 factors compared between the two stocks. Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNKD vs. The Competition Export to ExcelMetricMannKindMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.66B$3.19B$5.84B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio50.6421.4375.4125.98Price / Sales5.99429.44515.81181.13Price / Cash39.0546.6837.5660.44Price / Book-19.219.6112.156.29Net Income$27.59M-$53.29M$3.29B$271.07M7 Day Performance0.54%0.13%0.74%3.87%1 Month Performance50.54%5.55%5.00%5.49%1 Year Performance-11.16%10.44%62.55%25.86% MannKind Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNKDMannKind4.4177 of 5 stars$5.57+2.8%$11.17+100.5%-11.2%$1.66B$285.50M50.64400Positive NewsShort Interest ↓RGENRepligen4.8458 of 5 stars$120.70-3.1%$169.55+40.5%-18.9%$6.79B$634.44M-482.781,778Positive NewsAnalyst ForecastAnalyst RevisionALKSAlkermes4.5479 of 5 stars$28.45-5.0%$41.31+45.2%-2.5%$4.94B$1.56B13.731,800Trending NewsAnalyst ForecastHigh Trading VolumeLGNDLigand Pharmaceuticals4.199 of 5 stars$165.86-0.5%$176.50+6.4%+58.2%$3.27B$167.13M0.0080Positive NewsShort Interest ↑FOLDAmicus Therapeutics3.9591 of 5 stars$7.98-0.1%$16.00+100.5%-29.3%$2.46B$528.29M0.00480Positive NewsBCRXBioCryst Pharmaceuticals4.2487 of 5 stars$8.19-1.0%$16.70+103.9%-0.1%$1.74B$450.71M0.00530Positive NewsCLDXCelldex Therapeutics2.403 of 5 stars$23.40+2.3%$46.67+99.4%-44.6%$1.52B$7.02M0.00150Positive NewsINVAInnoviva4.8494 of 5 stars$20.46-0.1%$42.75+108.9%-2.2%$1.29B$358.71M12.72100Positive NewsAnalyst DowngradeShort Interest ↓NVAXNovavax4.4823 of 5 stars$7.73-2.2%$14.29+84.8%-41.4%$1.26B$682.16M3.391,990Positive NewsDVAXDynavax Technologies4.458 of 5 stars$9.70-3.6%$24.33+150.9%-15.8%$1.18B$277.25M50.30350Positive NewsOPKOPKO Health4.398 of 5 stars$1.42+5.2%$2.75+93.7%-10.8%$1.13B$713.10M-5.682,997 Related Companies and Tools Related Companies Repligen Alternatives Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives Celldex Therapeutics Alternatives Innoviva Alternatives Novavax Alternatives Dynavax Technologies Alternatives OPKO Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNKD) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredAmerica’s most terrifying chart?MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
